Category: Media

Femasys Receives AMA CPT Editorial Panel Approval for New Category III CPT Code for FemaSeed Intratubal Insemination

FemaSeed FAQs – from cost to success rates, these are the questions you’re asking

Femasys Expands European Commercial Footprint with Swiss Partner for FemBloc, FemaSeed, and Portfolio Products

Femasys Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Requirement

Femasys Announces Partnership with Refuah Health Center to Expand First-Line Access to FemaSeed® in Community-Based Care

Femasys Secures U.S. FDA Clearance for Next-Generation FemVue Diagnostic Device

Scott Chudnoff, MD, highlights the benefits of Fembloc for permanent contraception

Femasys Announces Third Quarter Financial Results for 2025

Femasys Advances Global Growth with Second Partner Order for FemBloc® in Europe

How Femasys Is Using Innovation to Rethink Permanent Birth Control